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Abstract
Background:  A range of strategies have been adopted to prevent early onset Group B
Streptococcal (EOGBS) sepsis, as a consequence of Group B Streptococcal (GBS) vertically
acquired infection. This study was designed to provide a scientific basis for optimum timing and
method of GBS screening in an Australian setting, to determine whether screening for GBS
infection at 35–37 weeks gestation has better predictive values for colonisation at birth than
screening at 31–33 weeks, to examine the test characteristics of a risk factor strategy and to
determine the test characteristics of low vaginal swabs alone compared with a combination of
perianal plus low vaginal swabs per colonisation during labour.
Methods: Consented women received vaginal and perianal swabs at 31–33 weeks gestation, 35–
38 weeks gestation and during labour. Swabs were cultured on layered horse blood agar and
inoculated into selective broth prior to analysis. Test characteristics were calculated with exact
confidence intervals for a high risk strategy and for antenatal screening at 31–33 and 35–37 weeks
gestation for vaginal cultures alone, perianal cultures alone and combined low vaginal and perianal
cultures.
Results: The high risk strategy was not informative in predicting GBS status during labour. There
is an unequivocal benefit for the identification of women colonised with GBS during labour
associated with delaying screening until 36 weeks however the results for method of screening
were less definitive with no clear advantage in using a combined low vaginal and perianal swabbing
regimen over the use of a low vaginal swab alone.
Conclusion: This study can contribute to the development of prevention strategies in that it
provides clear evidence for optimal timing of swabs. The addition of a perianal swab does not
confer clear benefit. The quantification of advantages and disadvantages provided in this study will
facilitate communication with clinicians and pregnant women alike.
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Background
Group B Streptococcus (GBS) infection in infants as a con-
sequence of vertically acquired infection, is an important
cause of neonatal mortality and morbidity, presenting as
sepsis or pneumonia [1]. The incidence of early onset
group B streptococcus sepsis (EOGBS) occurring within
the first week of life has fallen in Australia from 2.0 per
1000 live births in 1991–1993 to 0.5 per 1000 live births
in 1995–1997 [2]. This figure is similar to the recently
reported annual incidence of 0.48 per 1000 from the
United Kingdom and Ireland [3].
Vaginal colonisation occurs in 11–30% of all pregnant
women [4-6] and 50–75% of their infants become colo-
nised usually during labour or birth. There is clear evi-
dence that intrapartum colonisation is strongly associated
with EOGBS sepsis [7] which has a case-fatality of approx-
imately 4%[1]. Serious morbidities include sepsis, pneu-
monia, meningitis, osteomyelitis or septic arthritis.
The United States' Centers for Disease Control has
endorsed a strategy in which screening of pregnant
women is to occur at 35–37 weeks gestation using vaginal
and rectal swabs and all women delivering before 37
weeks are to be treated if they are of GBS culture positive
or of unknown GBS status, a change from their previous
policy in which a strategy of intrapartum chemoprophy-
laxis based on a risk-based approach also was endorsed
[8]. This contrasts with the 2003 recommendation from
the Royal College of Obstetricians and Gynaecologists
which states that "routine screening (either bacteriologi-
cal or risk based) for antenatal GBS carriage is not recom-
mended" [9]. There is no standard accepted approach to
the prevention of EOGBS. Strategies have evolved includ-
ing screening antenatally to detect colonisation or treat-
ment of women with risk factors including prolonged
rupture of membranes, intrapartum fever, preterm labour
and history of maternal colonisation during pregnancy
reflecting in part, the impact of local data on the burden
of GBS.
Within Australia there is considerable variation in clinical
practice in both the prevention of GBS sepsis in neonates
and in practitioner opinions as to the appropriate
approach to screening for and treatment of GBS [10]. Such
variation in views amongst obstetricians and neonatolo-
gists reflects uncertainty about the application of differing
hospital guidelines.
The current strategy at The Women's and Children's Hos-
pital (WCH) in Adelaide for the prevention of GBS infec-
tion in the newborn includes the administration of
prophylactic antibiotics during labour to women identi-
fied as being colonised with GBS, following universal
screening with prenatal low vaginal cultures at 32 weeks
gestation.
This study was designed to provide a scientific basis for
optimum timing and method of GBS screening as speci-
fied in guidelines for antenatal care, to determine whether
screening for GBS infection at 35–37 weeks gestation has
better predictive values for colonisation at birth than
screening at 31–33 weeks, to examine the test characteris-
tics of a risk factor strategy and to determine the test char-
acteristics of low vaginal swabs alone compared with a
combination of perianal plus low vaginal swabs per colo-
nisation during labour.
Methods
Study population
Women were eligible for inclusion if they had a singleton
pregnancy, attended the Women's and Children's Hospi-
tal for their antenatal care over a 13-month period from
May 1998 to May, 1999 and expected to deliver at that
hospital at term. Women with previous GBS disease were
included as were women enrolled in a shared care pro-
gram between general practitioners and the hospital. Eth-
ics committee approval was obtained from the Women's
and Children's Hospital.
Recruitment
Information sessions were held for antenatal clinic and
labour ward staff prior to the commencement of recruit-
ment and during the recruitment period, to familiarise
staff with the study and incorporate their suggestions into
the study protocol if appropriate. Women were informed
about the study after their 18-week morphological scan
and approached for consent at approximately 28 weeks
gestation. Women who consented received vaginal and
perianal swabs at 31–33 weeks, 35–38 weeks and during
labour. A sample of these women participated in focus
groups to explore their views about the collection of
swabs antenatally and intra-partum, their attitudes to the
prophylactic administration of antibiotics during labour
and their understanding about GBS infection [11].
Although we had intended at the outset to recruit private
patients, we could not develop cost-effective strategies for
their involvement.
Patient management
Participants had a low vaginal swab taken at 31–33 weeks
for detection of GBS, the current protocol at the WCH.
Standard recommendations for taking swabs were given
to clinic staff to ensure that low vaginal swabs were taken
without a speculum, by inserting the swab 2–3 cm. into
the vagina and rotating the swab with a circular motion,
leaving it in the vagina for approximately 5 seconds. A
separate perianal swab was taken by gently rotating theBMC Pregnancy and Childbirth 2005, 5:12 http://www.biomedcentral.com/1471-2393/5/12
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swab around the anal margin for approximately five sec-
onds. The swabs were placed in Stuart transport medium
for transport to the laboratory within two hours.
At 35–37 weeks additional swabs (vaginal and perianal)
were taken in the antenatal clinic by study staff following
the protocol described above. The results of both screen-
ing swabs were made available to the caregivers. Women
found on antenatal screening to be GBS carriers were rec-
ommended to have intrapartum antibiotics as per the
hospital clinical guidelines.
When women were admitted in labour, a further vaginal
and perianal swab was taken for culture by the admitting
midwife to determine intrapartum colonisation. Note was
made of whether the membranes had ruptured prior to
the swab. Medical records for study participants contained
an eye-catching sticker to remind labour ward staff that
both a perianal and a vaginal swab needed to be taken. In
addition, participants were given a card identifying them
as participants in the "SWABS" study, to be handed to
labour ward staff as a prompt for the taking of swabs.
Study midwives provided inservice training on the proto-
col for taking labour swabs to staff in emergency, labour
ward and the birthing centre.
Microbiology
Upon receipt in the microbiology laboratory, the swabs
were cultured on layered horse blood agar and inoculated
into a selective broth (Todd Hewitt broth containing gen-
tamicin 4 mg/L and nalidixic acid 15 mg/L). The agar
plate was incubated at 35°C in a carbon dioxide-enriched
environment for 18–24 hours, and the broth was incu-
bated at 35°C overnight, subcultured onto layered horse
blood agar and incubated as above. Plates were inspected
for β-hemolytic colonies and Streptococci were identified
according to standard laboratory procedures. Presumptive
GBS colonies were confirmed using the Phadebact latex
agglutination method. Growth on the plate was semi-
quantified as described by [12]. Growth from broth only
was described as "scanty".
Data collection and management
Data were collected to define the characteristics of the
population including age, insurance status, socioeco-
nomic status, parity, weight at booking, smoking status at
booking, previous known GBS infection, asymptomatic
bacteriuria, GBS screening at booking, previous preterm
birth or preterm prelabour rupture of membranes.
Women were classified as being at high risk if they had
any of the following risk factors; GBS bacteruria at book-
ing, birth at <37 weeks' gestation, prelabour rupture of
membranes or temperature during labour of greater than
or equal to 38 degrees Centigrade. Data were keyed into
the study computer database (Microsoft ACCESS) with
range checking, logic checking and verification of key
fields.
Analyses
Sensitivities, specificities, positive predictive values and
negative predictive values for colonisation at birth, are
reported with exact confidence intervals for antenatal
screening at 31–33 (referred to as 32 weeks) and 35–37
weeks gestation (referred to as 36 weeks) for vaginal cul-
tures alone (LVS), perianal cultures alone (PAS) and com-
bined low vaginal and perianal cultures (either).
Likelihood ratios were calculated to express the odds that
a given level of a diagnostic test result would be expected
in a woman colonised at term. Diagnostic odds ratios and
their exact 95% confidence interval are an indication of
the strength of the association between having a positive
likelihood ratio and being diseased.
These test characteristics were compared to identify the
best method of screening as determined by site of swab,
timing and the interaction between site and timing, using
a multinominal logit model with the weighted least
squares method of estimation. The interaction term was
not statistically significant and thus the results of the main
effects models alone are reported [13].
Different screening strategies were examined to determine
the relative value of screening at 8 weeks prior to expected
birth (with the potential for lower predictive values but
with the potential also for the identification of women
colonised with GBS who may give birth between 32 and
35–37 weeks and screening closer to term or using risk
factors to identify likely to be colonised at birth.
Sample Size
The sample size was calculated assuming a weighted least
squares analysis [14]. Calculations were based on assump-
tions concerning estimates of prevalence of GBS infection
at the WCH at the time of routine screening (13%) and at
birth (10%) (McDonald, personal communication). We
assumed that the positivity rate at a 36-week screen would
be 13%. Research published prior to the design of this
study reported that a late antenatal screen had a sensitivity
of approximately 87% [15]. Using a more conservative
estimate of 80.5 percent, a sample size of approximately
839 was adequate to detect a sensitivity of 87% or greater.
Alpha was set at 0.05 and β was selected to be 0.2. The cor-
relation between estimated sensitivities at the two time
periods was estimated to be approximately 0.7.
Results
A total of 865 women, of the 1168 approached, consented
to participate in the SWABS study giving a participation
rate of 74% (Figure 1). A number of these women (35)
withdrew from the study over the period of follow-up,BMC Pregnancy and Childbirth 2005, 5:12 http://www.biomedcentral.com/1471-2393/5/12
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reflecting mobility of the patient population (9), reluc-
tance of the woman or her partner to continue (21), a
reaction to a positive test (3) and unknown reasons (2).
Swabs were obtained from 93% of participants at 32
weeks, the time of the routine hospital antenatal screen
for GBS. At 36 weeks swabs were taken from 94% of
women who had neither given birth nor withdrawn while
labour swabs were taken for 84% of women who had not
withdrawn.
Study participants reflected the composition of the low-
risk antental clinic at the Women's and Children's Hospi-
tal (Table 1) in their age, gravidity, parity and model of
care. Thirty women (3.5%) were positive for GBS with
bacteriuria at booking, although these results were not
known for over 13% of participants. Of the 48% of
women with a previous pregnancy who reached 20 weeks
or more, 55 (13%) had a history of GBS carriage in a pre-
vious pregnancy. Only one woman reported a history of
having a child with neonatal GBS sepsis.
Colonisation rates were constant across the gestational
ages examined, with approximately 20% of all partici-
pants colonised regardless of the gestational age of screen-
ing and the swab site. At all times, the colonisation rate
was slightly higher with the perianal than the vaginal
swab. (Table 2). Colonisation rates would have been
reported as being between 14–17% if results for selective
broth were not included, approximately 5% lower than
those actually identified using the broth.
Using the risk factor algorithm a total of 146 women
(18% of the 830 women who did not withdraw, 95% CI
15% – 20%) would have been identified as being eligible
for intrapartum antibiotic chemoprophylaxis.
Analysis of the test characteristics associated with different
screening schedules was undertaken for the subset of 600
(69%) study participants for whom complete data were
available from testing at 32 weeks and 36 weeks gestation
as well as in labour (Table 3). Analysis of the use of a risk
Recruitment and data collection Figure 1
Recruitment and data collection. LVS Low vaginal swab PAS Perianal swab
Withdrawn before 32 week swab 18
Deliver before 32 week swab 3
No swab taken 42
Swab lost 1
LVS only 65
PAS only 2
LVS + PAS 734
Any swab taken 802
32 Week swab expected 865
Withdrawn before 36 week swab 12
Deliver between 32 + 36 week swab 26
No swab taken 15
LVS only 5
PAS only LVS lost 1
LVS + PAS 785
Any swab taken 791
36 week swab expected 844
Withdrawn before labour swab 5
No swab taken 127
LVS only 3
PAS only 1
LVS + PAS 699
Any swab taken 703
Labour swab expected 835
Swabs consent = 865
Women approached N=1168BMC Pregnancy and Childbirth 2005, 5:12 http://www.biomedcentral.com/1471-2393/5/12
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factor protocol was undertaken for the 699 participants
for whom a labour swab was taken (Table 3). It was appar-
ent that tests at 36 weeks were more sensitive and had
higher negative predictive values and lower Likelihood
Ratio negative values than tests at 32 weeks. There were no
statistically significant differences in specificity, positive
predictive value or Likelihood Ratio positive values asso-
ciated with the timing of screening. Having a positive peri-
anal or low vaginal swab – the more inclusive definition,
was a more sensitive test than low vaginal swab alone but
with a trade-off in terms of specificity and positive
predictive value. There was no statistical difference in the
Likelihood Ratio positive, but Likelihood Ratio negative
was lower using the more inclusive definition of positivity
(Table 4). Classifying women as being at high risk was not
sensitive (Table 3) and was not informative in predicting
GBS status during labour (Likelihood ratio tests were not
different than 1).
Multivariate analysis examined the impact of timing
(screening at 36 rather than 32 weeks) and method of
screening (low vaginal swabs or both low vaginal and
perianal swabs) (Table 4). The interaction between
method and timing was not significant. It was clear that
there is an unequivocal benefit associated with delaying
screening until 36 weeks. The results for method of screen-
ing were less definitive. Although sensitivity, negative pre-
dictive value and likelihood ratio negative were improved
using a combined low vaginal and perianal swabbing reg-
imen, the LVS swab alone was associated with higher spe-
cificity and positive predictive value.
Discussion
This study has demonstrated that colonisation during
pregnancy with Group B Streptococcus is common
amongst a low risk antenatal population. Regardless of
the timing of the testing, approximately 20% of women
were identified with a positive swab and therefore would
have been eligible, using the hospital protocol, for
antibiotic use during labour. Although this colonisation
rate is a little lower than that reported by Yancy et al. in
their investigation of timing of swabs in 826 women
(26.5% vs approx 20% in this study) there were slight dif-
ferences in the study population with the former study
excluding women who had received antibiotics within a
week prior to birth. The test characteristics reported from
the Yancy study (Sensitivity 87%, Specificity 96%, PPV
87%, NPV 96%) were all stronger than in this current
study (36 weeks screen: Sensitivity 81%, Specificity 93%,
PPV 77%, NPV 94%). Likelihood ratios and diagnostic
odds ratios were not reported for the former study.
This study provides clear evidence about screening timing
and strategy in order to identify women colonised with
GBS in labour, with more equivocal evidence about meth-
ods. Screening for GBS infection at 35–37 weeks gestation
has better test characteristics and predictive values for col-
onisation at birth than screening at 31–33 weeks. As the
Table 1: Characteristics of the 865 participants (Means and 
standard deviations or numbers and (percentages)).
Characteristic Mean (sd)
or Number
(%)
Age Mean (sd) 28.0 (5.5)
Age group
≤ 20 74 (8.6)
21–34 680 (78.6)
≥ 35 111 (12.8)
Parity
0 447 (51.7)
1–3 402 (46.5)
≥ 4 16 (1.8)
Model of care (booking)
Traditional + midwifery antenatal care 461 (53.3)
Birth Centre 185 (21.4)
GP Shared Care 219 (25.3)
Smoking at booking 185
(21.4%)
GBS bacteriuria at booking
Positive (4% of all with known values) 30 (3.5%)
Unknown 117
(13.5%)
History of GBS among women with parity 1+ (n = 418)
Positive in previous pregnancy (27.3% of known) 55 (13.2)
Unknown 184 (44%)
History of neonatal GBS sepsis n = 418 1 (0.2)
Unknown 26 (36.2)
History of
Preterm birth 32 (7.7)
Preterm prelabour rupture of membranes 12 (2.9)
Sociodemographic characteristics
Race
Caucasian 818 (94.6)
Aboriginal/Torres Strait Islander 8 (0.9)
Asian 35 (4.0)
Other 4 (0.5)
Education
School student 5 (0.6)
Left school aged < 16 55 (6.4)
Left school aged ≥ 16 369 (42.7)
Trade qualification 36 (4.2)
Certificate or Diploma 241 (27.9)
Bachelors Degree or higher 159 (18.4)BMC Pregnancy and Childbirth 2005, 5:12 http://www.biomedcentral.com/1471-2393/5/12
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hospital in which this research was undertaken has a pol-
icy of routine administration of antibiotics to women at
risk of preterm birth, a delay in the timing of screening
would not exclude those women at higher risk for GBS
infection. In an environment in which this was not policy
however, screening at 35–37 weeks may miss a particu-
larly high-risk group.
We have defined 'high risk' as GBS bacteruria at booking,
preterm birth <37 weeks' gestation, prelabour rupture of
membranes or pyrexia in labour (temperature greater
than or equal to 38 degrees Centrigrade). The test charac-
teristics of a screening strategy using these risk factors are
relatively poor although the use of a non-independent ref-
erence standard (colonisation in labour identified follow-
ing LVS and PVS) is an issue. This finding reinforces those
from a multisite study sponsored by the Centers for Dis-
ease Control [16] whose guidelines state that a risk-based
strategy is not supported.
Table 2: Colonisation rates (%) and 95% confidence intervals by gestational age and swab sitea. Using selective broth
a. Using selective broth
Swab site 32 weeks gestation 36 weeks gestation Labour
Prevalence 95 % CI Prevalence 95% CI Prevalence 95% CI
Low Vaginal Swab (LVS) 19 16–21 20 17–23 21 18–24
Perianal Swab (PAS) 21 18–24 22 19–25 22 19–25
Either LVS or PAS 22 19–25 24 21–26 24 21–27
b. Removing "scanty" levels of colonisation as would occur in the absence of selective broth
Swab site 32 weeks gestation 36 weeks gestation Labour
Prevalence 95 % CI Prevalence 95% CI Prevalence 95% CI
Low Vaginal Swab (LVS) 14 11–16 15 13–18 17 14–20
Perianal Swab (PAS) 15 12–18 15 12–17 16 13–19
Either LVS or PAS 17 15–20 18 16–21 20 17–23
Table 3: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative likelihood ratios 
with 95% confidence intervals for screening at 32 weeks or 36 weeks, using low vaginal (LVS) and/or perianal (PAS) swabs for 600 
women and for using a risk factor strategy*.
32 Weeks (n = 600) 36 Weeks (n = 600) (n= 699)
LVS PAS Either LVS PAS Either
Estimate + 
95% CI
Estimate + 
95% CI
Estimate + 
95% CI
Estimate + 
95% CI
Estimate + 
95% CI
Estimate + 
95% CI
Estimate + 
95% CI
Sensitivity 63 54–71 70 61–77 72 63–79 73 65–81 76 67–83 81 73–87 19 13–26
Specificity 94 92–96 94 91–96 93 90–95 95 93–97 94 91–96 93 90–95 83 79–86
PPV* 77 68–84 76 68–84 75 66–82 82 74–88 78 70–85 77 69–84 25 18–34
NPV 90 87–92 91 89–94 92 89–94 92 90–95 93 90–95 94 92–96 77 73–80
Likelihood ratio (+ve) 11.3 7.6–
16.7
11.2 7.7–
16.2
10.1 7.2–
14.3
15.5 10.2-
23.6
12.1 8.4-
17.5
11.7 8.3-
16.6
1.10 0.76-
1.59
Likelihood ratio (-ve) 0.39 0.31–
0.49
0.32 0.25–
0.42
0.30 0.23–
0.40
0.28 0.21–
0.37
0.26 0.19–
0.35
0.21 0.15–
0.29
0.98 0.90–
1.06
Diagnostic Odds Ratio 28.7 16.4–
50.6
34.5 19.8–
60.4
33.4 19.4–
57.9
55.4 30.1–
103
46.5 26.1–
83.1
56.7 31.4–
103
1.12 0.69–
1.79
* Risk factor strategy included women with GBS bacteruria at booking, birth at <37 weeks' gestation, prelabour rupture of membranes or 
temperature during labour of greater than or equal to 38 degrees Centrigrade.BMC Pregnancy and Childbirth 2005, 5:12 http://www.biomedcentral.com/1471-2393/5/12
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Low vaginal swabs, perinanal, or combined?
The use of both low vaginal swabs and perianal swabs
identifies a higher proportion of colonised women.
Whether in fact this higher antepartum detection rate will
contribute to lower rates of neonatal infection and mor-
bidity has yet to be determined. The additional costs of
such an approach would need to be examined to deter-
mine whether hospital guidelines should be altered.
There is variability in screening practices in clinical prac-
tice nationally and worldwide. The companion paper
from this study reporting the results of qualitative inter-
views with participants highlights that pregnant women
are keen to do everything possible to ensure that they have
a healthy liveborn infant and, that swabbing is not seen as
particularly intrusive. Although these women expressed
little concern about the potential adverse effects of antibi-
otic use [11] such concern is an appropriate one for
healthcare workers.
Conclusion
This study has many strengths. A very high proportion of
eligible patients agreed to participate and follow-up rates
were high. The approach used to taking swabs and to their
subsequent analysis is in accord with current best practice.
A more detailed approach to the statistical analysis of the
data is presented than has been reported in prior research.
The study had the ability to examine the potential impact
of a high risk strategy and a screening strategy among the
same women. What this study cannot do is provide much
needed direct evidence about the relative effectiveness of
different strategies in terms of prevention of Early Onset
GBS. Such evidence would require the conduct of very
large randomised controlled trials which to date have not
been seen to be feasible. For this reason, evidence from
studies such as this is essential for institutions developing
screening policies.
List of abbreviations used
CI Confidence Interval
EOGBS Early Onset Group B Streptococcal Sepsis
GBS Group B Streptococcus
LVS Low vaginal swabs
NPV Negative predictive value
PAS Perianal swabs
PPV Positive predictive value
WCH Women's and Children's Hospital
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